Skye Bioscience, Inc. Earnings Per Share Disclosure
| For the Year Ended December 31, 2025 | |||||||||||||||||
| Loss (Numerator) | Shares (Denominator) | Per-Share Amount | |||||||||||||||
| Net loss | $ | (55,924,814) | |||||||||||||||
| Basic EPS and diluted EPS | |||||||||||||||||
| Net loss available to common stockholders | (55,924,814) | 39,662,664 | $ | (1.41) | |||||||||||||
| For the Year Ended December 31, 2024 | |||||||||||||||||
| Income (Numerator) | Shares (Denominator) | Per-Share Amount | |||||||||||||||
| Net loss | $ | (26,567,123) | |||||||||||||||
| Basic EPS and diluted EPS | |||||||||||||||||
| Net loss available to common stockholders | (26,567,123) | 36,486,519 | $ | (0.73) | |||||||||||||
| Year Ended December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Stock options | 4,528,555 | 3,036,603 | |||||||||
| Unvested restricted stock units | 492,488 | 503,113 | |||||||||
| Warrants | 3,089,182 | 3,202,944 | |||||||||
| Total | 8,110,225 | 6,742,660 | |||||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.